Evidence map›Paper›PMID 40510792›Full record

ArticleInternational journal of pharmaceutics: X2025

A pragmatic mixing model for the evaluation of powder flow properties of multicomponent pharmaceutical blends.

Daniel Yanes, Rachael Shinebaum, Georgios Papakostas, Gavin K Reynolds, Sadie M E Swainson

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel YanesOral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom.
Rachael ShinebaumOral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom.
Georgios PapakostasEarly Product Development and Manufacturing, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Macclesfield SK10 2NA, United Kingdom.
Gavin K ReynoldsOral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom.
Sadie M E SwainsonOral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maintaining flowability of pharmaceutical blends is critical for operational efficiency in state-of-the-art continuous direct compression (CDC) manufacturing, with poor flow potentially resulting in API loss, increased experimental work and increased time to market. Consequently, flowability is a crucial consideration in the design of formulations and must be considered throughout the development process when changes are introduced. Traditionally, understanding flow properties has required testing large amounts of material, particularly when evaluating formulation options. This has led to research into developing predictive flow models to reduce experimental burden. Current models with good predictive capacity, such as using granular bond number, require non-routine measurements such as mechanical surface energy. Three mixture designs, each using three pharmaceutical materials, were developed to investigate flow properties and allow the evaluation of a number of mixing models for predicting flowability with minimal experimental input requirements. The resultant models ranged in complexity from simple first order mixture models to more complex third order models with binary and ternary interaction parameters. An analysis of the experimental cost versus prediction accuracy suggested that while the more complex models delivered the most accurate predictions, a first order mass weighted model using inverse FFC was capable of providing good predictions in return for a more manageable experimental burden, with an R

Indexed as

Continuous direct compressionDesign of experimentPharmaceutical powder flowPowder blendsPredictive modellingShear cell

Identifiers

PMID40510792
PMCPMC12159881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.